Antifibrotic activities of pirfenidone in animal models

Glutamate neurotoxicity and diseases of the nervous system

Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,152 · see citing works

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias

(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196 · see citing works

Mechanisms of Hepatic Fibrogenesis

Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,640 · see citing works

Molecular Regulation of Hepatic Fibrosis, an Integrated Cellular Response to Tissue Injury

Friedman, S. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.4.2247 · Cited by 2,067 · see citing works

Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy

Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,790 · see citing works

Incidence and Prevalence of Idiopathic Pulmonary Fibrosis

Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · see citing works

Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis

Phillips, R. J., Burdick, M. D., Hong, K. M., Lutz, M., Murray, L. A., Xue, Y., Belperio, J. A., Keane, M. P., & Strieter, R. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20997 · Cited by 1,071 · see citing works

The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · see citing works

High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis

Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964 · see citing works

Pirfenidone in idiopathic pulmonary fibrosis

Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 957 · see citing works

Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 953 · see citing works

NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury

Hecker, L., Vittal, R., Jones, T., Jagirdar, R., Luckhardt, T. R., Horowitz, J. C., Pennathur, S., Martinez, F. J., & Thannickal, V. J. (2009) · Nature Medicine · doi:10.1038/nm.2005 · Cited by 852 · see citing works

Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–

Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 802 · see citing works

Potential Therapeutic Targets for Cardiac Fibrosis

Leask, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.217737 · Cited by 661 · see citing works

Molecular insights into renal interstitial fibrosis.

Eddy, A. A. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7122495 · Cited by 641 · see citing works

Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans

Zuo, F., Kaminski, N., Eugui, E. M., Allard, J. D., Zohar Yakhini, B., Ben‐Dor, A., Lollini, L. O., Morris, D. G., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620 · see citing works

Expression of connective tissue growth factor in human renal fibrosis

Ito, Y., Aten, J., Bende, R. J., Oemar, B. S., Rabelink, T. J., Weening, J. J., & Goldschmeding, R. (1998) · Kidney International · doi:10.1111/j.1523-1755.1998.00820.x · Cited by 558 · see citing works

Role of Epithelial Cells in Idiopathic Pulmonary Fibrosis: From Innocent Targets to Serial Killers

Selman, M., & Pardo, A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-003tk · Cited by 528 · see citing works

Oxidative stress and glutathione in TGF-β-mediated fibrogenesis

Liu, R.-M., & Pravia, K. A. G. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.026 · Cited by 468 · see citing works

Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, Pirfenidone: Results of a Prospective, Open-label Phase II Study

Raghu, G., Johnson, W. C., Lockhart, D., & Mageto, Y. N. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9805017 · Cited by 468 · see citing works

Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology

Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 463 · see citing works

Gene Expression Profiles Distinguish Idiopathic Pulmonary Fibrosis from Hypersensitivity Pneumonitis

Selman, M., Pardo, A., Barrera, L., Estrada, A., Watson, S. R., Wilson, K., Aziz, N. A., Kaminski, N., & Zlotnik, A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-644oc · Cited by 455 · see citing works

Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis

Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 434 · see citing works

Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations

Prud’homme, G. J. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700669 · Cited by 424 · see citing works

Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis

Andersson‐Sjöland, A., de Alba, C. G., Nihlberg, K., Becerril, C., Ramı́rez, R., Pardo, A., Westergren‐Thorsson, G., & Selman, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.02.012 · Cited by 360 · see citing works

Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model

Chaudhary, N. I., Schnapp, A., & Park, J. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-717oc · Cited by 359 · see citing works

Atrial fibrosis and the mechanisms of atrial fibrillation

Everett, T. H., & Olgin, J. E. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.12.040 · Cited by 338 · see citing works

Pulmonary Fibrosis

Chua, F., Gauldie, J., & Laurent, G. J. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0062tr · Cited by 305 · see citing works

New Mechanisms of Pulmonary Fibrosis

Strieter, R. M., & Mehrad, B. (2009) · CHEST Journal · doi:10.1378/chest.09-0510 · Cited by 287 · see citing works

Accelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern

Selman, M., Carrillo, G., Estrada, A., Mejía, M. E., Becerril, C., Cisneros, J., Gaxiola, M., Pérez‐Padilla, R., Navarro, C., Richards, T. J., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000482 · Cited by 270 · see citing works

Strategies for treating idiopathic pulmonary fibrosis

du Bois, R. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2958 · Cited by 246 · see citing works

Pirfenidone Prevents the Development of a Vulnerable Substrate for Atrial Fibrillation in a Canine Model of Heart Failure

Lee, K. W., Everett, T. H., Rahmutula, D., Palmero, M. J. G., Wilson, E., Ding, C., & Olgin, J. E. (2006) · Circulation · doi:10.1161/circulationaha.106.624320 · Cited by 224 · see citing works

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R., & Kopp, J. B. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01050207 · Cited by 222 · see citing works

Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters.

Iyer, S. N., Wild, J. S., Schiedt, M. J., Hyde, D. M., Margolin, S. B., & Giri, S. N. (1995) · PubMed · Cited by 217 · see citing works

Oxidative stress in the pathogenesis of diffuse lung diseases: A review

Bargagli, E., Olivieri, C., Bennett, D., Prasse, A., Müller–Quernheim, J., & Rottoli, P. (2009) · Respiratory Medicine · doi:10.1016/j.rmed.2009.04.014 · Cited by 216 · see citing works

Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndrome

Gahl, W. A., Brantly, M., Troendle, J. F., Avila, N. A., Padua, A., Montalvo, C., Cardona, H., Calis, K. A., & Gochuico, B. R. (2002) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(02)00044-6 · Cited by 202 · see citing works

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level

Nakazato, H., Oku, H., Yamane, S., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01758-2 · Cited by 187 · see citing works

Molecular Phenotypes Distinguish Patients with Relatively Stable from Progressive Idiopathic Pulmonary Fibrosis (IPF)

Boon, K., Bailey, N., Yang, J., Steel, M. P., Groshong, S. D., Kervitsky, D. J., Brown, K. K., Schwarz, M. I., & Schwartz, D. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005134 · Cited by 183 · see citing works

Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level

Gurujeyalakshmi, G., Hollinger, M. A., & Giri, S. N. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.276.2.l311 · Cited by 180 · see citing works

Effects of Pirfenidone on Procollagen Gene Expression at the Transcriptional Level in Bleomycin Hamster Model of Lung Fibrosis

Iyer, S. N., Gurujeyalakshmi, G., & Giri, S. N. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38125-x · Cited by 179 · see citing works

Pirfenidone effectively reverses experimental liver fibrosis

García‐Benavides, L., Hernández‐Cañaveral, I., Sandoval-Rodriguez, A. S., Salazar, A., Garcia, J., Vera-Cruz, J. M., Grijalva, G., Muriel, P., Margolin, S. B., & Armendáriz‐Borunda, J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00272-6 · Cited by 172 · see citing works

Re-evaluation of Fibrogenic Cytokines in Lung Fibrosis

Kelly, M. M., Kolb, M. R. J., Bonniaud, P., & Gauldie, J. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033392341 · Cited by 170 · see citing works

Gene Expression Profiling of Familial and Sporadic Interstitial Pneumonia

Yang, I. V., Burch, L. H., Steele, M. P., Savov, J. D., Hollingsworth, J. W., McElvania, E., Berman, K., Speer, M. C., Sporn, T. A., Brown, K. K., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200601-062oc · Cited by 169 · see citing works

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis

Kakugawa, T., Mukae, H., Hayashi, T., Ishii, H., Abe, K., Fujii, T., Oku, H., Miyazaki, M., Kadota, J., & KOHNO, S. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00120803 · Cited by 167 · see citing works

Pirfenidone inhibits the expression of HSP47 in TGF-β1-stimulated human lung fibroblasts

Nakayama, S., Mukae, H., Sakamoto, N., Kakugawa, T., Yoshioka, S., Soda, H., Oku, H., Urata, Y., Kondo, T., KUBOTA, H. Y., et al. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.11.003 · Cited by 165 · see citing works

Pirfenidone Is Renoprotective in Diabetic Kidney Disease

RamachandraRao, S., Zhu, Y., Ravasi, T., McGowan, T., Toh, I., Dunn, S., Okada, S., Shaw, M., & Sharma, K. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008090931 · Cited by 165 · see citing works

Non-steroid agents for idiopathic pulmonary fibrosis

Spagnolo, P., Giovane, C. D., Luppi, F., Cerri, S., Balduzzi, S., Walters, E. H., D’Amico, R., & Richeldi, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003134.pub2 · Cited by 161 · see citing works

Pirfenidone improves renal function and fibrosis in the post-obstructed kidney

Shimizu, T., Kuroda, T., Hata, S., Fukagawa, M., Margolin, S. B., & Kurokawa, K. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00962.x · Cited by 161 · see citing works

Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock

Oku, H., Nakazato, H., Horikawa, T., Tsuruta, Y., & Suzuki, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01757-0 · Cited by 158 · see citing works

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production

Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00245-3 · Cited by 138 · see citing works

Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals

Misra, H. P., & Rabideau, C. L. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007023532508 · Cited by 132 · see citing works

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive rats

Mirkovic, S., Seymour, A. L., Fenning, A. S., Strachan, A. J., Margolin, S. B., Taylor, S. M., & Brown, L. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704539 · Cited by 129 · see citing works

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias

Nguyen, D. T., Ding, C., Wilson, E., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.04.030 · Cited by 127 · see citing works

Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon’s Fibroblasts In Vitro

Lin, X., Yu, M., Wu, K., Yuan, H., & Zhong, H. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2815 · Cited by 115 · see citing works

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease

Cho, M. E., & Kopp, J. B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903501539 · Cited by 111 · see citing works

Idiopathic pulmonary fibrosis: new insights into pathogenesis

Noble, P. W., & Homer, R. (2004) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2004.04.003 · Cited by 108 · see citing works

Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro

Grattendick, K. J., Nakashima, J., Feng, L., Giri, S. N., & Margolin, S. B. (2008) · International Immunopharmacology · doi:10.1016/j.intimp.2008.01.013 · Cited by 106 · see citing works

Lung Fibrosis is Ameliorated by Pirfenidone Fed in Diet After the Second Dose In A Three-Dose Bleomycin-Hamster Model

Iyer, S. N., Margolin, S. B., Hyde, D. M., & Giri, S. N. (1998) · Experimental Lung Research · doi:10.3109/01902149809046058 · Cited by 105 · see citing works

Pirfenidone: A Novel Pharmacological Agent That Inhibits Leiomyoma Cell Proliferation and Collagen Production

Lee, B. S., Margolin, S. B., & Nowak, R. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.1.4503 · Cited by 101 · see citing works

Potent antioxidant role of Pirfenidone in experimental cirrhosis

Salazar-Montes, A., Ruiz-Corro, L., López-Reyes, A. G., Castrejón-Gómez, E., & Armendáriz‐Borunda, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.110 · Cited by 98 · see citing works

Bleomycin-induced pulmonary fibrosis. Effects of steroid on lung collagen metabolism.

Phan, S. H., Thrall, R. S., & Williams, C. (1981) · PubMed · doi:10.1164/arrd.1981.124.4.428 · Cited by 96 · see citing works

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults

Rubino, C. M., Bhavnani, S. M., Ambrose, P. G., Forrest, A., & Loutit, J. (2009) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2009.03.003 · Cited by 95 · see citing works

Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy.

Shimizu, T., Fukagawa, M., Kuroda, T., et al. (1997) · PubMed · Cited by 92 · see citing works

A pilot study in patients with established advanced liver fibrosis using pirfenidone

Armendáriz‐Borunda, J., Islas-Carbajal, M. C., Meza-García, E., et al. (2006) · Gut · doi:10.1136/gut.2006.107136 · Cited by 87 · see citing works

Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

Hewitson, T. D., Kelynack, K. J., Tait, M. G., Martic, M., Jones, C. L., Margolin, S. B., & Becker, G. J. (2001) · PubMed · Cited by 86 · see citing works

The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen α1(I), TIMP-1 and MMP-2

Sario, A. D., Bendia, E., Macarri, G., Candelaresi, C., Taffetani, S., Marzioni, M., Omenetti, A., Minicis, S. D., Trozzi, L., & Benedetti, A. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.05.012 · Cited by 85 · see citing works

Asthma and COPD

Welte, T., & Groneberg, D. A. (2006) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2006.02.004 · Cited by 84 · see citing works

Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge

Hirano, A., Kanehiro, A., Ono, K., Ito, W., Yoshida, A., Okada, C., Nakashima, H., Tanimoto, Y., Kataoka, M., Gelfand, E. W., et al. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0452oc · Cited by 83 · see citing works

Pirfenidone Inhibits Dimethylnitrosamine‐Induced Hepatic Fibrosis In Rats

Tada, S., Nakamuta, M., Enjoji, M., et al. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03481.x · Cited by 78 · see citing works

Effects of pirfenidone on the generation of reactive oxygen species in vitro.

Giri, S. N., Leonard, S. S., Shi, X., Margolin, S. B., & Vallyathan, V. (1999) · PubMed · Cited by 77 · see citing works

Pirfenidone Inhibits Lung Allograft Fibrosis through L-Arginine–Arginase Pathway

Liu, H., Drew, P. A., Gaugler, A. C., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.00876.x · Cited by 76 · see citing works

Inhibitory Effects of a Lecithinized Superoxide Dismutase on Bleomycin-Induced Pulmonary Fibrosis in Mice

Kotaro, T., Taooka, Y., Maeda, A., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.4.9906099 · Cited by 72 · see citing works

Superoxide scavenging activity of pirfenidone–iron complex

Mitani, Y., Sato, K., Muramoto, Y., Karakawa, T., Kitamado, M., Iwanaga, T., Nabeshima, T., Maruyama, K., Nakagawa, K., Ishida, K., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.093 · Cited by 65 · see citing works

Renoprotective properties of pirfenidone in subtotally nephrectomized rats

Takakuta, K., Fujimori, A., Chikanishi, T., Tanokura, A., Iwatsuki, Y., Yamamoto, M., Nakajima, H., Okada, M., & Itoh, H. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.011 · Cited by 50 · see citing works

Fibrosis causes progressive kidney failure

Cohen, E. P. (1995) · Medical Hypotheses · doi:10.1016/0306-9877(95)90221-x · Cited by 47 · see citing works

Effect of pirfenidone against vanadate-induced kidney fibrosis in rats

Al-Bayati, M. A., Xie, Y., Mohr, F. C., Margolin, S. B., & Giri, S. N. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01213-3 · Cited by 46 · see citing works

Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration

Giri, S. N., Wang, Q., Xie, Y., et al. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.311 · Cited by 45 · see citing works

Pirfenidone Attenuates Bleomycin-Induced Changes in Pulmonary Functions in Hamsters

SCHELEGLE, E. S., Mansoor, J. K., & Giri, S. N. (1997) · Experimental Biology and Medicine · doi:10.3181/00379727-216-44187 · Cited by 42 · see citing works

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis

Azuma, A. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.32 · Cited by 41 · see citing works

Pirfenidone Inhibits Obliterative Airway Disease in Mouse Tracheal Allografts

Zhou, H., Latham, C., Zander, D. S., Margolin, S. B., & Visner, G. A. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.11.002 · Cited by 38 · see citing works

Pirfenidone: A Novel Pharmacological Agent That Inhibits Leiomyoma Cell Proliferation and Collagen Production

Lee, B.-S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.1.219 · Cited by 30 · see citing works

Current clinical trials for the treatment of idiopathic pulmonary fibrosis

Klingsberg, R. C., Mutsaers, S. E., & Lasky, J. A. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01672.x · Cited by 26 · see citing works

The Experimental Agent Pirfenidone Reduces Pro-Fibrotic Gene Expression in a Model of Tacrolimus-Induced Nephrotoxicity

Brook, N. R., Waller, J. R., Bicknell, G. R., et al. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2004.12.007 · Cited by 26 · see citing works

Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells

Zhang, S., Shiels, I. A., Ambler, J., & Taylor, S. M. (1998) · Australian and New Zealand Journal of Ophthalmology · doi:10.1111/j.1442-9071.1998.tb01380.x · Cited by 25 · see citing works

Pharmacokinetics of orally administered pirfenidone in male and female beagles

Bruss, M. L., Margolin, S. B., & Giri, S. N. (2004) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2004.00612.x · Cited by 22 · see citing works

The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model

Brook, N. R., Waller, J. R., Bicknell, G. R., et al. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.12.150 · Cited by 16 · see citing works

The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).

Noble, P. W., Albera, C., Bradford, W., Costabel, U., Kardatzke, D. R., T King, Jr., Sahn, S. A., Szwarcberg, J., Valeyre, D., & du Bois, R. M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a1129 · Cited by 16 · see citing works

Matrix Metalloproteinases in Tissue Remodelling and Inflammation

Parnham, M. J., Lagente, V., & Boichot, E. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8585-9 · Cited by 15 · see citing works

Pirfenidone.

Lasky, J. A. (2004) · PubMed · Cited by 13 · see citing works

DEVELOPMENT OF A HIGH THROUGHPUT COLLAGEN ASSAY USING A CELLULAR MODEL OF IDIOPATHIC PULMONARY FIBROSIS

Özeş, O. N., & Blatt, L. M. (2006) · CHEST Journal · doi:10.1378/chest.130.4_meetingabstracts.230s-a · Cited by 10 · see citing works

PIRFENIDONE MEDIATES DIFFERENTIAL EFFECTS ON LIPOPOLYSACCHARIDE-INDUCED CYTOKINE EXPRESSION IN HUMAN PERIPHERAL MONONUCLEAR CELLS

Phillips, R. J., Wang, T., Blatt, L. M., et al. (2005) · CHEST Journal · doi:10.1378/chest.128.4_meetingabstracts.169s-a · Cited by 5 · see citing works

Role of matrix metalloproteases in pulmonary fibrosis

Pardo, A., & Selman, M. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8585-9_3 · Cited by 4 · see citing works

Late breaking clinical trials

ORIENT Study Investigators, & ASCEND Study Group (2009) · NDT Plus · doi:10.1093/ndtplus/2.s2.1 · Cited by 4 · see citing works

Growth Factors

Kolb, M. R. J., Xing, Z., & Gauldie, J. (2002) · Elsevier eBooks · doi:10.1016/b978-012079028-9/50105-8 · Cited by 2 · see citing works

Idiopathic pulmonary fibrosis

Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020 · see citing works

Immune mechanisms in pulmonary fibrosis

Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349 · see citing works

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts

Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · see citing works

An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial

Khanna, D., Albera, C., Fischer, A., Khalidi, N., Raghu, G., Chung, L., Chen, D., Schiopu, E., Tagliaferri, M., Seibold, J. R., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.151322 · Cited by 268 · see citing works

Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer

Takai, K., Le, A., Weaver, V. M., & Werb, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12658 · Cited by 207 · see citing works

Combination therapy: the future of management for idiopathic pulmonary fibrosis?

Wuyts, W. A., Antoniou, K. M., Borensztajn, K., Costabel, U., Cottin, V., Crestani, B., Grutters, J. C., Maher, T. M., Poletti, V., Richeldi, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70232-2 · Cited by 150 · see citing works

Pirfenidone for idiopathic pulmonary fibrosis and beyond

Aimo, A., Spitaleri, G., Nieri, D., Tavanti, L. M., Meschi, C., Panichella, G., Lupón, J., Pistelli, F., Carrozzi, L., Bayes-Genis, A., et al. (2022) · Cardiac Failure Review · doi:10.15420/cfr.2021.30 · Cited by 88 · see citing works

Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts

Toda, M., Mizuguchi, S., Minamiyama, Y., Yamamoto-Oka, H., Aota, T., Kubo, S., Nishiyama, N., Shibata, T., & Takemura, S. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.17-111 · Cited by 42 · see citing works

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation

Ballester, B., Milara, J., & Cortijo, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27526 · Cited by 43 · see citing works

Mitochondrial Dysfunction in Aged Macrophages and Lung during Primary Streptococcus pneumoniae Infection is Improved with Pirfenidone

Plataki, M., Cho, S. J., Harris, R. M., Huang, H.-R., Yun, H. S., Schiffer, K. T., & Stout-Delgado, H. W. (2019) · Scientific Reports · doi:10.1038/s41598-018-37438-1 · Cited by 42 · see citing works

A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review

Man, R. K., Gogikar, A., Nanda, A., Janga, L. S. N., Sambe, H. G., Yasir, M., & Ramphall, S. (2024) · Cureus · doi:10.7759/cureus.54268 · Cited by 30 · see citing works

Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis

Zhang, Y., MacKenzie, B., Koleng, J. J., Maier, E., Warnken, Z. N., & Williams, R. O. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01085 · Cited by 27 · see citing works

Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience

Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106551 · Cited by 19 · see citing works

A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects

Cheung, D., Fong, A., Ding, H. T., Cabanski, C. R., Wang, J., Chen, Y., Bush, J., Harris, J. M., & Pan, L. (2021) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2021.102051 · Cited by 6 · see citing works

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial

Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., et al. (2026) · American Journal of Respiratory and Critical Care Medicine · doi:10.1093/ajrccm/aamag155 · Cited by 4 · see citing works

Efficacy of Pirfenidone in Patients With the Advanced Stage of Idiopathic Pulmonary Fibrosis

Sakamoto, S., Ishida, F., Satoh, K., et al. (2011) · CHEST Journal · doi:10.1378/chest.1114180 · Cited by 2 · see citing works

Pirfenidone treatment of idiopathic pulmonary fibrosis

Azuma, A. (2012) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465812436663 · Cited by 57 · see citing works

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe

Kaushal, M., Talwar, D., Prajapat, D. K., Kumar, S., Acharya, S., & Talwar, D. (2022) · Cureus · doi:10.7759/cureus.22606 · Cited by 4 · see citing works

Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis

Kwapiszewska, G., Birnhuber, A., Wilhelm, J., Marsh, L. M., Puthenparampil, H. T., Sinn, K., Didiášová, M., Klepetko, W., Kosanovic, D., SCHERMULY, R. T., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.00564-2018 · Cited by 80 · see citing works

Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease

Jenkins, G. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-206209 · Cited by 3 · see citing works